Table 1 Demographics and clinical characteristics
From: Exercise and epigenetic ages in older adults with myeloid malignancies
Variables |  | N = 20 |
|---|---|---|
Age in years, mean (SD, range) |  | 71.2 (4.8, 62–80) |
Gender, n (%) | Male | 13 (65.0) |
Female | 7 (35.0) | |
Race, n (%) | White | 18 (90.0) |
Black or African American | 1 (5.0) | |
Prefer not to say | 1 (5.0) | |
Ethnicity, n (%) | Not Hispanic or Latino | 19 (95.0) |
Prefer not to say | 1 (5.0) | |
Marital status, n (%) | Married | 13 (65.0) |
Divorced or widowed | 2 (10.0) | |
Single | 5 (25.0) | |
Education, n (%) | High school or below | 2 (10.0) |
At least some college | 6 (30.0) | |
College graduate | 5 (25.0) | |
Postgraduate level | 6 (30.0) | |
Prefer not to say | 1 (5.0) | |
Karnofsky performance status, n (%) | 90–100 | 3 (15.0) |
70–80 | 12 (60.0) | |
50–60 | 5 (25.0) | |
Diagnosis, n (%) | AML | 11 (55.0) |
MDS | 8 (40.0) | |
MDS/myeloproliferative neoplasm overlap syndromes | 1 (5.0) | |
Treatment, n (%) | HMA combination treatment (e.g., venetoclax) | 11 (55.0) |
HMA only | 7 (35.0) | |
Other* | 2 (10.0) | |
Chemotherapy cycle at initiation of intervention, n (%)* | 1 | 3 (15.0) |
2 | 9 (45.0) | |
3 | 4 (20.0) | |
 ≥ 4 | 4 (20.0) |